Patients' perspective in the decision and reimbursement process for direct-acting oral anticoagulants for atrial fibrillation and venous thromboembolic disease
Date
2015
Authors
Brouwers, J.
Hendriks, J.
Van Laarhoven, H.
Jukema, G.
Pronk, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Pharmaceutisch weekblad, 2015; 150(16):72-78
Statement of Responsibility
J.R.B.J. Brouwers, Jeroen M L Hendriks, Hans van Laarhoven, G.J. Jukema
Conference Name
Abstract
OBJECTIVE: To develop a method to incorporate practice-based knowledge of medical doctors, pharmacists, nurses and patients in treatment guidelines and in reimbursement decisions. DESIGN AND METHODS: Based on literature review and expert opinion of medical professionals a decision tree is developed for assessment of DOACs from patients' perspective in the treatment of non-valvular atrial fibrillation [nvAF] and venous thromboembolic disease (VTE). RESULTS: For both nvAF and VTE six relevant patient aspects were identified: target INR, safe use, therapy compliance, organisation of care, wellbeing and self-management. When comparing DOACs with standard VKA-containing treatment for these conditions, DOACs showed added value regarding four patient aspects in nvAF and five aspects in VTE. As an example, relevant aspects for DOACs are: easy dosage regimen, self-management of drug use and wellbeing. None of these aspects are represented in the current decision process for guidelines and reimbursement. CONCLUSION: Dealing with relevant criteria from a patients' perspective in a decision tree, DOACs have potential added value that should be considered in guideline development and reimbursement decisions.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright status unknown